54.3 F
San Diego
Thursday, Mar 28, 2024
-Advertisement-

Clarification

In a story appearing Oct. 2 (“Short Sellers Swarming Avanir’s Stock, Driving Down Share Price”), the Business Journal reported biotech analyst John McCamant said he does not think Avanir Pharmaceuticals’ drug Neurodex would receive approval from the federal Food and Drug Administration. After publication, McCamant clarified his statement: He said that the current political climate at the FDA would make approvals difficult for drugs that treat chronic diseases, such as Neurodex.

-Advertisement-

Featured Articles

-Advertisement-
-Advertisement-

Related Articles

-Advertisement-
-Advertisement-
-Advertisement-